U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: DOW, et al.		
Application No./Patent No.: 10/621,254	Filed/Issue Date: July 14, 2003	
Entitled: VACCINES USING PATTERN RECOGNITION RECEPTOR-LIGAND:LIPID COMPLEXES		
JUVARIS BIOTHERAPEUTICS, INC (Name of Assignee)	a Corporation (Type of Assignee, e.g., corporation, partnership,	university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest;	or	
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is 50%)		
in the patent application/patent identified above by virtue of either:		
 An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel <u>014667</u>, Frame <u>0808</u>, or for which a copy thereof is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 		
1. From:	To:	
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
2. From:	To:	
The document was recorded in the United States Patent and Trademark Office at		
Reel, Frame, or for which a copy thereof is attached.		
3. From: To: To: To: The document was recorded in the United States Patent and Trademark Office at		
Reel, Frame, or for which a copy thereof is attached.		
Additional documents in the chain of title are listed on a supplemental sheet.		
As required by 37 CFR 3.73(b)(1)(i), the documents or concurrently is being, submitted for recordation p		riginal owner to the assignee was,
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. <u>See</u> MPEP 302.08]		
The undersigned (whose title is supplied below) is authorized.	orized to act on behalf of the assignee.	17 Dec., 2008
John F. Warner, Ph.D.		Date (650) 259-1800
Printed or Typed Name Chief Scientific Officer, Vice President, Resear BioTherapeutics, Inc. Title	rch & Development, Juvaris	Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.